VALBIOTIS presents positive results from a study on TOTUM-63, active substance of VALEDIA®
VALBIOTIS presents positive results from a study on TOTUM-63, active substance of VALEDIA®, conducted by the CarMeN laboratory in Lyon, at the Annual Meeting of the European Association for the Study of Diabetes (EASD)
- This preclinical study conducted by the CarMeN laboratory, expert in metabolic diseases, confirms the major effects of the active substance TOTUM-63 on weight and glucose metabolism.
- Data demonstrates capacity of TOTUM-63 to significantly correct the secretion of three hormones, essential for blood glucose regulation (insulin, glucagon and GLP-1) in a preclinical model of metabolic disease.
- These results have been selected for presentation at the 55th EASD Annual Meeting which will be held September 16-20, 2019 in Barcelona.
La Rochelle, 16 September 2019 (5:40 PM CEST) – VALBIOTIS (FR0013254851 – ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced the presentation of a preclinical study conducted by the CarMeN laboratory on the active substance TOTUM-63, at the 55th Annual Meeting of the European Association for the Study of Diabetes being held September 16-20, 2019 in Barcelona, Spain.
Diary - News
All news VALBIOTIS presents positive results from a study on TOTUM-63, active substance of VALEDIA® 